Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Transplant Recipient Clear all
Terminated Not applicable Interventional

Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients

NCT02174783
View directory record Official record
Conditions
Liver Transplantation, Metabolic Syndrome X, Obesity
Interventions
Control group, Mediterranean diet, Protein-Sparing Modified Fast (PSMF)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated Phase 4 Interventional Results available

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

NCT03625687
View directory record Official record
Conditions
Respiratory Failure, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Withdrawn Phase 4 Interventional

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

NCT03026023
View directory record Official record
Conditions
Cardiac Transplant Disorder, Hepatitis C
Interventions
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 27, 2026, 4:53 AM EDT
Not yet recruiting Not applicable Interventional

Intervention for Alcohol Use Disorder Recovery After Liver Transplantation

NCT07214259
View directory record Official record
Conditions
Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Interventions
Online Sober Active Community, Recovery coach
Behavioral
Lead sponsor
Leigh Anne Dageforde
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

NCT03811873
View directory record Official record
Conditions
Metabolic Bone Disease, Transplant-Related Disorder, Secondary Osteoporosis
Interventions
Dual x-ray absorptiometry, Vertebral Fracture Assessment
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Completed No phase listed Observational

Quality of Life in Pediatric Transplant Recipients

NCT00209196
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional

Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients

NCT03249194
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C
Interventions
Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed No phase listed Observational

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

NCT00531921
View directory record Official record
Conditions
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 70 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Ithaca, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed No phase listed Observational

Evaluation of the Impact of Reduced Immunosuppression

NCT05238155
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
antimetabolite
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

NCT02118896
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Kidney Transplantation
Interventions
FK506E
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 27, 2026, 4:53 AM EDT
Withdrawn Phase 4 Interventional

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

NCT03623568
View directory record Official record
Conditions
Kidney Failure, Kidney Diseases, Hepatitis C
Interventions
glecaprevir/pibrentasvir tablets
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
30 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

NCT04057001
View directory record Official record
Conditions
Liver Transplant; Complications, Hepatitis C
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

NCT03208244
View directory record Official record
Conditions
End Stage Heart Disease, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Active, not recruiting Phase 4 Interventional

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

NCT05325073
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
Erythropoietin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 27, 2026, 4:53 AM EDT
Withdrawn Phase 4 Interventional

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

NCT05275907
View directory record Official record
Conditions
High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions
Amlodipine Besylate, Chlorthalidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional

HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients

NCT06386198
View directory record Official record
Conditions
Liver Transplant; Complications
Interventions
Health Advocate
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 4:53 AM EDT
Withdrawn Not applicable Interventional

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Liver Transplant Recipients

NCT03515330
View directory record Official record
Conditions
Medication Adherence, Liver Transplant
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

NCT00336817
View directory record Official record
Conditions
Immunosuppression
Interventions
Myfortic, CellCept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 27, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 27, 2026, 4:53 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 27, 2026, 4:53 AM EDT